


## Gefitinib

<b>Cat. No.:</b>	HY-50895		
<b>CAS No.:</b>	184475-35-2		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>24</sub> ClFN <sub>4</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	446.9		
<b>Target:</b>	EGFR; Autophagy; Apoptosis		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Autophagy; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (223.76 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	2.2376 mL	11.1882 mL	22.3764 mL
<b>5 mM</b>	0.4475 mL	2.2376 mL	4.4753 mL
<b>10 mM</b>	0.2238 mL	1.1188 mL	2.2376 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: corn oil  
Solubility: 5 mg/mL (11.19 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (5.59 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
- Add each solvent one by one: 1% DMSO >> 99% saline  
Solubility: 0.5 mg/mL (1.12 mM); Suspended solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC<sub>50</sub> of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC<sub>50</sub> of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer

	related research, such as Lung cancer and breast cancer <sup>[1][2][5]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	EGFR																
<b>In Vitro</b>	<p>Gefitinib (0.01-0.1 μM, 72 h) results in increased phosphotyrosine load of the receptor, increased signalling to ERK and stimulation of proliferation and anchorage-independent growth<sup>[2]</sup>.</p> <p>Gefitinib (1-2 μM, 72 h) significantly decreases EGFRvIII phosphotyrosine load, EGFRvIII-mediated proliferation and anchorage-independent growth<sup>[2]</sup>.</p> <p>Gefitinib (0.62 μM, 24-72 h) inhibits IL-13-induced M2-like polarization of RAW 264.7 cells through the STAT6-dependent signaling pathway<sup>[3]</sup>.</p> <p>Gefitinib (0.62 μM, 72 h) inhibits M2-like macrophage-promoted invasion and migration<sup>[3]</sup>.</p> <p>Gefitinib (0-10 μM, 72 h) induces apoptosis (induction of BIM protein) in NSCLC Cell Lines (H3255 and HCC827 cells)<sup>[4]</sup>.</p> <p>Gefitinib (100 nM, 24 h) suppresses macropinocytosis and increases the cellular uptake of extracellular vesicles (EVs) in HCC827 and A549 cells<sup>[6]</sup>.</p> <p>Gefitinib (1.5-60 μM, 48 h) increases inhibition of proliferation in H358<sup>R</sup> and A549<sup>R</sup> cells (Cisplatin-resistant wtEGFR NSCLC cell lines)<sup>[7]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>NR6wtEGFR, NR6W and NR6M</td> </tr> <tr> <td>Concentration:</td> <td>1, 10, 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>5 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited EGFR tyrosine phosphorylations.</td> </tr> </table> <p>Cell Migration Assay <sup>[3]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>LLCs cell</td> </tr> <tr> <td>Concentration:</td> <td>0.62 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Abrogated M2-like macrophage promoted invasion and migration of LLCs.</td> </tr> </table>	Cell Line:	NR6wtEGFR, NR6W and NR6M	Concentration:	1, 10, 100 μM	Incubation Time:	5 h	Result:	Inhibited EGFR tyrosine phosphorylations.	Cell Line:	LLCs cell	Concentration:	0.62 μM	Incubation Time:	72 h	Result:	Abrogated M2-like macrophage promoted invasion and migration of LLCs.
Cell Line:	NR6wtEGFR, NR6W and NR6M																
Concentration:	1, 10, 100 μM																
Incubation Time:	5 h																
Result:	Inhibited EGFR tyrosine phosphorylations.																
Cell Line:	LLCs cell																
Concentration:	0.62 μM																
Incubation Time:	72 h																
Result:	Abrogated M2-like macrophage promoted invasion and migration of LLCs.																
<b>In Vivo</b>	<p>Gefitinib (Oral administration, 75 mg/kg/d, 21 days) inhibits the M2-like polarization of macrophages in LLC mice metastasis model<sup>[3]</sup>.</p> <p>Gefitinib (Oral administration, 75 mg/kg for the initial week, daily for 5 consecutive days per week) eliminates phosphorylation of HER2 and HER3 and signaling through MAPK and Akt in lobular hyperplasias and carcinomas, increases MAPK activity and cytokine production in splenocytes and lymph nodes<sup>[5]</sup>. Gefitinib (Oral gavage, 150 mg/kg, daily) enhances the anti-tumor effect of Cisplatin in H358<sup>R</sup> xenograft<sup>[7]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>LLC mice metastasis model<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>75 mg/kg/d, for 21 days.</td> </tr> <tr> <td>Administration:</td> <td>Oral administration</td> </tr> <tr> <td>Result:</td> <td>Reduced the number of lung metastasis nodules, down-regulated the expression of M2 marker genes and the percentages CD206<sup>+</sup> and CD68<sup>+</sup> macrophages in tumor tissues.</td> </tr> </table>	Animal Model:	LLC mice metastasis model <sup>[3]</sup>	Dosage:	75 mg/kg/d, for 21 days.	Administration:	Oral administration	Result:	Reduced the number of lung metastasis nodules, down-regulated the expression of M2 marker genes and the percentages CD206 <sup>+</sup> and CD68 <sup>+</sup> macrophages in tumor tissues.								
Animal Model:	LLC mice metastasis model <sup>[3]</sup>																
Dosage:	75 mg/kg/d, for 21 days.																
Administration:	Oral administration																
Result:	Reduced the number of lung metastasis nodules, down-regulated the expression of M2 marker genes and the percentages CD206 <sup>+</sup> and CD68 <sup>+</sup> macrophages in tumor tissues.																

Animal Model:	BALB-NeuT transgenic mouse model <sup>[5]</sup>
Dosage:	75 mg/kg for the initial week, and increased by 15 mg/kg every other week, daily for 5 consecutive days per week, followed by 2 days without treatment and repeated for 8–9 weeks.
Administration:	Oral administration
Result:	Reduced tumor multiplicity from 9.6 to 0.58 (83%), and reduced the number and size of lobules and lobular nodules in treated mice.

## CUSTOMER VALIDATION

- Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.
- Cell Res. 2021 Jun;31(6):631-648.
- Cell Res. 2020 Oct;30(10):833-853.
- Signal Transduct Target Ther. 2019 Dec 13;4:60.
- Nat Biomed Eng. 2018 Aug;2(8):578-588.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. *Br J Cancer*. 2005 Oct 17;93(8):915-23.
- [2]. Muhammad Tariq, et al. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. *Acta Pharmacol Sin*. 2017 Nov;38(11):1501-1511.
- [3]. Mark S Cragg, et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. *PLoS Med*. 2007 Oct;4(10):1681-89; discussion 1690.
- [4]. Marie P Piechocki, et al. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. *Int J Cancer*. 2008 Apr 15;122(8):1722-9.
- [5]. Tomoya Takenaka, et al. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. *Int J Pharm*. 2019 Dec 15;572:118762.
- [6]. Amin Li, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. *J Cancer Res Clin Oncol*. 2020 Jul;146(7):1737-1749.
- [7]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. *Cancer Res*. 2002 Oct 15;62(20):5749-54.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA